文献速递基础与转化研究临床试验与 GCP

Idecabtagene Vicleucel治疗复发难治性多发性骨髓瘤

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
PubMed 文献 · N Engl J Med · 2021-01-01

这项2期研究评估了靶向BCMA的CAR-T疗法ide-cel在复发难治性多发性骨髓瘤中的疗效与安全性。140例入组患者中128例接受治疗,总缓解率73%,完全缓解或更好33%,MRD阴性率26%,中位无进展生存期8.8个月。多数患者出现3/4级毒性,以血液学毒性和细胞因子释放综合征最常见。

要点

  • ide-cel在重度经治复发难治骨髓瘤中总缓解率达73%
  • 完全缓解或更好为33%,MRD阴性占全部治疗患者26%
  • 中位无进展生存期8.8个月,3/4级毒性几乎见于所有患者

核心结论

  • ide-cel在多数重度经治复发难治性骨髓瘤患者中诱导缓解,26%的治疗患者达到MRD阴性。
  • 几乎所有患者出现3或4级毒性,最常见为血液学毒性和细胞因子释放综合征。

研究设计与样本

  • 这是一项2期研究,旨在确认ide-cel在复发难治性骨髓瘤中的疗效和安全性。
  • 入组患者为至少接受过三种既往方案(包括蛋白酶体抑制剂、免疫调节剂和抗CD38抗体)后仍有疾病者。
  • 患者接受ide-cel目标剂量150×10^6至450×10^6 CAR阳性T细胞。
  • 主要终点为总缓解(部分缓解或更好),关键次要终点为完全缓解或更好(含完全缓解和严格完全缓解)。
  • 共入组140例患者,其中128例接受了ide-cel治疗。

主要发现

  • 中位随访13.3个月时,128例中94例(73%)有缓解,42例(33%)达到完全缓解或更好。
  • 33例确认MRD阴性(<10^-5有核细胞),占全部128例治疗患者的26%,占42例完全缓解或更好患者的79%。
  • 中位无进展生存期为8.8个月(95%CI 5.6–11.6)。
  • 128例治疗患者中常见毒性包括中性粒细胞减少117例(91%)、贫血89例(70%)、血小板减少81例(63%)。
  • 细胞因子释放综合征107例(84%),其中7例(5%)为3级或以上;神经毒性23例(18%),4例(3%)为3级,无高于3级者。

关键数值与推荐

  • 主要终点总缓解定义为部分缓解或更好;关键次要终点完全缓解或更好含完全缓解和严格完全缓解。
  • MRD阴性定义为<10^-5有核细胞。
  • 细胞动力学分析显示输注后6个月49例中29例(59%)、12个月11例中4例(36%)可检出CAR阳性T细胞。

临床怎么用

  • ide-cel可用于至少三线治疗(含蛋白酶体抑制剂、免疫调节剂和抗CD38抗体)后的复发难治性骨髓瘤。
  • 治疗前需预期并管理高频的血液学毒性和细胞因子释放综合征。
  • MRD阴性可作为完全缓解或更好患者的深度缓解指标进行监测。

局限性

  • 本文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma. Patients with disease after at least three previous regimens including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody were enrolled. Patients received ide-cel target doses of 150 × 106 to 450 × 106 CAR-positive (CAR+) T cells. The primary end point was an overall response (partial response or better); a key secondary end point was a complete response or better (comprising complete and stringent complete responses). RESULTS: Of 140 patients enrolled, 128 received ide-cel. At a median follow-up of 13.3 months, 94 of 128 patients (73%) had a response, and 42 of 128 (33%) had a complete response or better. Minimal residual disease (MRD)-negative status (<10-5 nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better. The median progression-free survival was 8.8 months (95% confidence interval, 5.6 to 11.6). Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%). Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher. Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred. Cellular kinetic analysis confirmed CAR+ T cells in 29 of 49 patients (59%) at 6 months and 4 of 11 patients (36%) at 12 months after infusion. CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021. PMID: 33626253. doi:10.1056/NEJMoa2024850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。